Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 5069

Drug Profile

AZD 5069

Alternative Names: AZD5069

Latest Information Update: 18 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; MedImmune
  • Class Antiasthmatics; Antineoplastics; Small molecules
  • Mechanism of Action Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Coronary disorders; Head and neck cancer; Non-small cell lung cancer; Solid tumours
  • Phase I/II Pancreatic cancer
  • Discontinued Asthma; Bronchiectasis; Chronic obstructive pulmonary disease

Most Recent Events

  • 22 Nov 2018 Phase-II clinical trials in Bladder cancer (Combination therapy) in USA (PO) (MedImmune pipeline, November 2018)
  • 22 Nov 2018 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy) in USA (PO) (MedImmune pipeline, November 2018)
  • 19 Oct 2018 Updated efficacy and adverse events data from a phase Ib/II SCORES trial in Head and neck cancer presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top